mRNA Vaccines and Therapeutics Market Analysis 2026

Global mRNA Vaccines and Therapeutics Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

mRNA Vaccines and Therapeutics Market Report Description

We have various report editions of mRNA Vaccines and Therapeutics Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The April 2025 “Liberation Day Tariffs” (10–46%) have disrupted global pharmaceutical trade, raising costs for APIs, packaging, and machinery from China and India. Generic drug makers, biopharma, vaccines, and CMOs face higher expenses, supply chain delays, and regulatory hurdles, while EU retaliation has further strained U.S. exports. Clinical trials are also delayed due to tariffs on drugs and kits. In this landscape, market research is vital, providing real-time data on pricing, suppliers, and tariff impacts to help companies optimize supply chains, find alternative hubs, and maintain competitiveness.

Competitive Landscape of the mRNA Vaccines and Therapeutics Market

In order to develop more effective vaccines and therapeutics and to extend the use of mRNA technology beyond vaccines to a wider range of therapeutic applications, such as the treatment of cancer, cardiovascular diseases, and genetic disorders, the global market for mRNA vaccines and therapeutics is expanding significantly. In addition, businesses are collaborating and partnering with biotech companies, academic organizations, and other pharmaceutical corporations in order to expedite the development of mRNA vaccines and therapies.

January 2023: With the goal of providing individualized cancer treatments for up to 10,000 patients by the end of 2030, BioNTech SE, a multinational next-generation immunotherapy company, and the Government of the United Kingdom (UK) inked a Memorandum of Understanding (MoU) to expedite clinical trials for customized mRNA immunotherapies.

(Source:https://investors.biontech.de/news-releases/news-release-details/biontech-announces-strategic-partnership-uk-government-provide )

December 2022: CSL Limited declared that it and Arcturus Therapeutics Holdings Inc. have completed their worldwide partnership and licensing arrangement through its subsidiary, CSL Seqirus. The deal makes it possible to use Arcturus Therapeutics' late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology, which recently revealed the findings of a sizable COVID-19 Phase III vaccine efficacy study. This technology meets its primary and secondary endpoints of preventing infection and severe disease while maintaining a favourable safety and tolerability profile.

(Source:https://newsroom.csl.com/2022-12-12-CSL-Announces-Closing-of-Global-Collaboration-and-Licensing-Agreement-with-Arcturus-Therapeutics )

December 2022: Moderna, Inc., a biotechnology company that is at the forefront of messenger RNA (mRNA) therapeutics and vaccines, announced that the US FDA has granted it emergency use authorization (EUA) for its BA.4/BA.5 Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.222, in children aged 6 months to under 5 years.

(Source:https://investors.modernatx.com/news/news-details/2022/Moderna-Receives-FDA-Emergency-Use-Authorization-for-Omicron-Targeting-Bivalent-COVID-19-Booster-Vaccine-in-Children-6-Months-Through-5-Years-of-Age/default.aspx )

Top Companies Market Share in mRNA Vaccines and Therapeutics Industry: (In no particular order of Rank)

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive)

Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the mRNA Vaccines and Therapeutics Market

Which Region Dominates the mRNA Vaccines and Therapeutics Market in 2024?

According to Cognitive Market Research, North America currently dominates the mRNA Vaccines and Therapeutics market, and the region is expected to have significant growth during the projected period due to a number of factors, including the presence of both established and up-and-coming pharmaceutical companies, ultracold manufacturing and supply chains, a growing awareness of mRNA-based COVID-19 vaccines, a sharp increase in funding infusions for mRNA vaccine development, and a high rise in pipeline products.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). Increased investment in biotechnology, improvements in healthcare infrastructure, and an increasing emphasis on precision medicine are all factors contributing to this growth. Prospects include expanding applications beyond infectious diseases to oncology and genetic problems; Japan's efforts in personalized medicine and China's investment in messenger RNA research are two prominent examples.

The current report Scope analyzes mRNA Vaccines and Therapeutics Market on 6 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (East Africa, West Africa, North Africa, South Africa)

The above graph is for illustrative purposes only.

North America mRNA Vaccines and Therapeutics Market Analysis

According to Cognitive Market Research, the global mRNA Vaccines and Therapeutics market size was estimated at USD 9124.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 3449.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the mRNA Vaccines and Therapeutics market with a market size of USD 2879.69 million in 2024 and is projected to grow at a CAGR of 14.2% during the forecast period ascribed to the increased incidence of chronic and infectious diseases, such as diabetes, cancer, heart disease, and HIV.
• The Canada mRNA Vaccines and Therapeutics market had a market share of USD 437.98 million in 2024 and is projected to grow at a CAGR of 15.2% during the forecast period driven by the growing prevalence of target diseases, the rising cost of healthcare, and the development of manufacturing and research capacities.
• The Mexico mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 14.9% during the forecast period, with a market size of USD 332.13 million in 2024.

Europe mRNA Vaccines and Therapeutics Market Analysis

According to Cognitive Market Research, the global mRNA Vaccines and Therapeutics market size was estimated at USD 9124.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 2737.35 million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.7% from 2024 to 2031.

• The United Kingdom mRNA Vaccines and Therapeutics market had a market share of USD 459.87 million in 2024 and is projected to grow at a CAGR of 15.5% during the forecast period driven by the increasing prevalence of infectious and chronic diseases, the growing need for tailored therapy, and developments in synthetic biology.
• The France mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 13.9% during the forecast period, with a market size of USD 251.84 million in 2024.
• According to Cognitive Market Research, the German mRNA Vaccines and Therapeutics market size was valued at USD 542.00 million in 2024 and is projected to grow at a CAGR of 14.9% during the forecast period as a result of strong healthcare infrastructure, large R&D expenditures, and quick mRNA technology breakthroughs.
• The Italy mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 14.1% during the forecast period, with a market size of USD 235.41 million in 2024.
• The Russia mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 13.7% during the forecast period, with a market size of USD 424.29 million in 2024.
• The Spain mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 13.8% during the forecast period with a market size of USD 224.46 million in 2024
• The Luxembourg mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 14.8% during the forecast period, with a market size of USD 84.86 million in 2024.
• The Portugal mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 14.5% during the forecast period, with a market size of USD 57.48 million in 2024.
• The Greece mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 15.0% during the forecast period, with a market size of USD 32.85 million in 2024.
• The Rest of Europe's mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 13.4% during the forecast period, with a market size of USD 424.29 million in 2024.

Asia Pacific mRNA Vaccines and Therapeutics Market Analysis

According to Cognitive Market Research, the global mRNA Vaccines and Therapeutics market size was estimated at USD 9124.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 2098.64 million in 2024 and will grow at a compound annual growth rate (CAGR) of 18.2% from 2024 to 2031.

• According to Cognitive Market Research, the China mRNA Vaccines and Therapeutics market size was valued at USD 944.39 million in 2024 and is projected to grow at a CAGR of 17.7% during the forecast period because infectious diseases are becoming more common and people are becoming more conscious of the importance of taking preventative action.
• The Japan mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 16.7% during the forecast period, with a market size of USD 289.61 million in 2024.
• The India mRNA Vaccines and Therapeutics market had a market share of USD 251.84 million in 2024 and is projected to grow at a CAGR of 20.0% during the forecast period attributed to the rise in infectious and chronic illnesses like HIV, diabetes, cancer, and heart disease.
• The South Korean mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 17.3% during the forecast period, with a market size of USD 209.86 million in 2024.
• The Australian mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 17.9% during the forecast period, with a market size of USD 109.13 million in 2024.
• The South East Asia mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 19.2% during the forecast period, with a market size of USD 144.81 million in 2024.
• The Rest of Asia Pacific mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 18.0% during the forecast period, with a market size of USD 149.00 million in 2024.

South America mRNA Vaccines and Therapeutics Market Analysis

According to Cognitive Market Research, the global mRNA Vaccines and Therapeutics market size was estimated at USD 9124.5 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 456.23 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.6% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil mRNA Vaccines and Therapeutics market size was valued at USD 195.26 million in 2024 and is projected to grow at a CAGR of 16.2% during the forecast period driven by the expansion of manufacturing and research capabilities, the growing prevalence of target diseases, and the growing expense of healthcare.
• Argentina's mRNA Vaccines and Therapeutics market had a market share of USD 76.65 million in 2024 and is projected to grow at a CAGR of 16.5% during the forecast period driven by advancements in synthetic biology, the rising need for individualized treatment, and the rising incidence of infectious and chronic diseases.
• Colombia mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 15.4% during the forecast period, with a market size of USD 40.60 million in 2024.
• Peru mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 15.8% during the forecast period, with a market size of USD 37.41 million in 2024.
• Chile mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 15.9% during the forecast period, with a market size of USD 32.85 million in 2024.
• The Rest of Latin America's mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 14.7% during the forecast period, with a market size of USD 73.45 million in 2024.

Middle East mRNA Vaccines and Therapeutics Market Analysis

According to Cognitive Market Research, the global mRNA Vaccines and Therapeutics market size was estimated at USD 9124.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 182.49 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.9% from 2024 to 2031..

• The GCC Countries mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 16.7% during the forecast period, with a market size of USD 78.11 million in 2024 due to rapid advancements in mRNA technology, substantial R&D investments, and a robust healthcare system.
• The Egypt mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 16.2% during the forecast period, with a market size of USD 19.16 million in 2024.
• The South Africa mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 16.9% during the forecast period, with a market size of USD 28.83 million in 2024 because the prevalence of infectious diseases is rising and individuals are realizing how important it is to take prophylactic measures.
• The Turkey mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 15.4% during the forecast period, with a market size of USD 15.69 million in 2024.
• The Nigeria mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 15.0% during the forecast period, with a market size of USD 19.16 million in 2024.
• The Rest of the MEA mRNA Vaccines and Therapeutics market is projected to witness growth at a CAGR of 14.9% during the forecast period, with a market size of USD 21.53 million in 2024.

Author's Conclusion

Author's Detail

Supriya Yadav

Research Analyst

LinkedIn | Profile | Book Appointment

Supriya Yadav is a dedicated market research professional with expertise in the aerospace and defence industry. At Cognitive Market Research, she focuses on delivering strategic insights into aviation advancements, defence technologies, and global security trends shaping the future of the sector.

Her research covers areas such as military modernization, commercial aviation growth, space exploration, and defence procurement strategies. With a strong analytical mindset and attention to technological evolution, Supriya provides data-driven intelligence that supports innovation, strategic planning, and informed decision-making within the aerospace and defence domain.